Abstract 1742P
Background
The US Surveillance, Epidemiology and End Result (SEER) data indicate an increasing incidence of early-onset cancer across the GI tract. A female predominance has been shown for early-onset pancreatic cancer (EOPC) in the US. Due to environmental factors which may underlie the pathogenesis of early-onset cancer, incidence across the globe may differ. However, data regarding the incidence of gastrointestinal cancers in young patients in Europe is scarce. Therefore, we aimed to investigate patterns of GI cancers in young patients across various European countries.
Methods
National cancer registries of seven European countries - Germany, Netherlands, Spain, Slovenia, Norway, Czech Republic and Israel - were approached for absolute number of cancer incidences per age group (15-50 years in 5-year intervals) and the size of the population for each age group yearly from 2008-2018. Data was analyzed to calculate year-by-year the Average Annual Incidence Rate Change (AARC) and Average Annual Percent Change (AAPC).
Results
We observed heterogeneous patterns in different GI cancers across countries. An increase was noted in oesophageal cancer in females in the Czech Republic and Germany (AAPC 11.65% and 1.11% respectively) and slightly in males in the Netherlands (AAPC 0.88%) and Slovenia (AAPC 0.40%). Gastric cancer increased in females in Norway (AAPC 15.00%) and Slovenia (AAPC 11.90%). An increase in incidence of EOPC in men and women was noted in Germany, Norway and Netherlands and in females in Israel and Slovenia (AAPC 6.0%, 4.30% respectively). Early-Onset Colorectal cancer (EOCRC) is on the rise in men and women in Israel, Netherlands and Norway, while increasing only in males in the Czech Republic (AAPC 1.50%) and only in females in Slovenia (AAPC 5.40%). In Spain, only EOCRC showed an increased incidence.
Conclusions
The incidence of early-onset cancer along the GI tract displays differential patterns across countries, which differs from the trends observed in SEER data. In some GI cancers the incidence is stable between 2008-2018 and some are increasing mainly in women. Due to the environmental role in the pathogenesis of early-onset GI cancer, future studies should unravel potential etiologies especially with regard to gender-related factors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23